Abstract Several studies have demonstrated that perioperative hemodynamic optimization (or ''goal directed therapy'') using minimally invasive hemodynamic monitoring technologies has the ability to improve postoperative patients' outcome with lower complication rates, shorter hospital lengths of stay, and lower cost of surgery. This specific concept of goal-directed therapy (GDT) uses perioperative cardiac output monitoring and manipulation of physiologic parameters (dynamic parameters of fluid responsiveness) to guide intravenous fluids and inotropic therapy with the goal of ensuring adequate tissue perfusion. Recently, the evidence related to the implementation of GDT strategies has been considered strong enough to allow for the creation of national recommendations in the UK, in France, and by the European Society of Anaesthesiology. The aims of the programs are to apply best practices to high-risk surgical patients and requires the participation of all clinicians involved in patients' care. Considering the potential clinical and economic benefits of GDT protocols and the positive recommendations from influential scientific societies, more and more hospitals around the world have become interested in implementing hemodynamic optimization in their departments. This review provides the information about the evolution of hemodynamic monitoring from invasive to the more recent noninvasive devices, and how these devices can be used in the operating rooms through well-defined algorithms of GDT.
Introduction
It is estimated that approximately 240 million anesthesia procedures are performed annually around the world [1] . Of these, approximately 10 % (&24 million) are conducted on ''high risk'' patients. This subset disproportionally accounts for more than 80 % of the overall mortality related to surgery [2] . Moderate risk surgery is much more common and represents approximately 40 % of the entire annual surgical population (96 million patients a year). Thankfully, most of these patients continue on to have an uncomplicated postoperative course. However, it is estimated that approximately 30 % of these (&29 million patients a year) present with a ''minor'' postoperative complication, most commonly a gut injury inducing delayed enteral feeding, abdominal distension, nausea, vomiting, or wound complications [3] . Even if these complications are said to be ''minor,'' they still lead to increased postoperative treatment, a longer length of stay and an overall increase in the cost of the medico-surgical management. A recent international, prospective assessment of surgical outcomes (''EUSOS'' study) in non-cardiac surgical patients demonstrated that the mortality rate was high (4 %) and varied substantially across European countries, suggesting the need for national and even international guidelines to improve postoperative outcomes [4] . As above, we currently know that in most of these patients the postoperative complications are related to tissue hypoperfusion [3, 5] . Thus, one of the most important goals of the physician anesthesiologist in the operating room (OR) is to maintain proper tissue perfusion through the optimization of intravascular volume status and stroke volume. To achieve that goal, as stated by Arthur Guyton in his Textbook of Medical Physiology, one needs ''an adequate perfusion pressure in order to force blood into the capillaries of all organs and an adequate cardiac output (CO) to deliver oxygen and substrates, and to remove carbon dioxide and other metabolic products'' [6, 7] . However, while blood pressure monitoring is part of the American Society of Anesthesiologists (ASA) guidelines for basic monitoring [8] , CO is rarely monitored, even during high-risk surgery [9] . Fluid therapy in the OR has traditionally been guided by basic static parameters such as heart rate, blood pressure, urine output, peripheral oxygen saturation, and central venous pressure (CVP). Unfortunately, these variables have been shown to be poor predictors of intravascular volume or changes in CO in response to a volume expansion. Newer dynamic parameters relying on cardio-pulmonary interactions in patients under general anesthesia and mechanical ventilation have been developed and have consistently been shown to be superior to static parameters for the prediction of fluid responsiveness (defined as the percent change in stroke volume induced by volume expansion). These dynamic variables can be obtained using multiple modalities ranging from the more invasive arterial pressure waveforms [10, 11] to more recently available noninvasive approaches [12] [13] [14] . A large variety of CO monitoring devices are currently offered today that claim to allow for perioperative hemodynamic optimization. These technologies have rapidly evolved from very invasive to mini-invasive and even completely noninvasive devices. Despite such advances, clinicians are still unsure about how and which technology to use in their daily practice.
We should all keep in mind that such hemodynamic monitoring systems are simply measurement tools and to quote Dr. Michael Pinsky: ''no monitoring device, no matter how simple or sophisticated, will improve patients' outcome unless coupled to a treatment which itself improves outcome'' [15] . All these minimally invasive CO monitoring devices have the ability to improve postoperative patients' outcome with lower complication rates, shorter hospital lengths of stay, and lower cost of surgery [16] [17] [18] [19] if they are integrated into appropriate protocols that guide the therapeutic interventions. This specific concept of goal-directed therapy (GDT) uses manipulation of physiologic targets to guide intravenous fluids and inotropic therapy with the goal of improving CO and oxygen delivery and thus preventing tissue oxygen debt by maintaining adequate tissue perfusion. As CO is a critical component of tissue oxygen delivery, any monitoring device used to guide therapy ideally should measure CO. Beyond this, different devices and protocols emphasize the multiple components of GDT to varying degrees with no set conclusion on the ideal approach.
Recently, GDT evidence has been considered strong enough to allow for the creation of national recommendations in the UK, in France, and by the European Society of Anaesthesiology [20] [21] [22] . GDT has been recognized as the standard of care in the anesthesiology setting because it has demonstrated strong clinical evidence and benefit in reducing rates of postoperative complications. Despite these favorable results, widespread implementation of GDT has not yet been accomplished and this approach has been poorly adopted in clinical practice [9, 23] . In many cases, fluids are still administered without appropriate goals or monitoring and most physician anesthesiologists use a combination of empirical formulas and fixed-volume calculations to guide their fluid therapy. This can lead to adverse clinical outcomes related to either hypovolemia or hypervolemia (Table 1) . Both of these complications can potentially cause a decrease in oxygen delivery to the tissues which can then lead to an increase in postoperative morbidity (Fig. 1) [12] . As with most novel treatment strategies, there have also been studies arguing that GDT in high-risk surgery has no statistically significant benefit when compared to restrictive crystalloid administration [24, 25] . In a recent randomized clinical trial in high-risk patients undergoing major abdominal surgery, GDT did not reduce postoperative complications and 30-day mortality [26 •• ] . As more evidence concerning various clinical situations arises, the clinical settings most likely to benefit from GDT will be better elucidated. [28] . In the UK, the National Health Service (NHS) has even created financial incentives to ensure hospitals implement hemodynamic optimization as standard of care for at least 80 % of eligible patients. The aim of the ERAS program is to apply best practices to highrisk surgical patients and requires the participation of all clinicians involved in patients' care. In the United States, the PSH model has recently gained momentum as a ''patientcentered'' and ''team-based'' approach that guides the patient through the entire surgical procedure by developing protocols and guidelines to improve perioperative management with the physician anesthesiologist playing a central management role. The ultimate goal of a proper PSH system is a better coordination of care that employs increased standardization in order to reduce the variability between clinicians. This PSH design may soon become the standard of care in the US as it has been shown to result in improved clinical outcome [28, 29] . Considering the potential clinical and economic benefits of GDT protocols and the positive recommendations from influential scientific societies, more and more hospitals around the world have become interested in implementing hemodynamic optimization in their departments.
This review will be divided into three main portions. In the first, we will describe the evolution in the choice of monitors used to perform GDT, most notably a move away from pulmonary artery catheters toward minimally invasive and even totally noninvasive monitors of CO. As each of these devices calculate CO differently, we will quickly describe their main characteristics and limitations that should be considered when implementing clinical decisions making. In the second portion, we will analyze how these various devices have been used in the ORs through welldefined algorithms of GDT (depending on the types of surgery) and how it has impacted patient outcome. Lastly, we will describe the newer closed-loop GDT concept and see if it could be the future for applying GDT automatically.
Monitoring for Guiding GDT in the Operating Room
Anesthesiologists still use the traditional hemodynamic variables (heart rate, blood pressure, CVP, and urine output) to guide their perioperative fluid therapy. However, they have consistently been shown to be neither sensitive nor specific for evaluating fluid status as the signs of hypovolemia including tachycardia, hypotension, and oliguria may be present in euvolemia and absence during hypovolemia. In addition, Le Manach et al. [30] recently revealed that blood pressure (BP) changes could not be used to track stroke volume changes induced by volume loading. They also demonstrated that the relationship between arterial pressure, ventricular stroke volume, and venous return is not simple and certainly not linear. Consequently, CO optimization in the OR (which relies heavily on the idea that fluid administration increases venous return) cannot be adequately performed with monitoring only arterial pressure. Studies analyzing GDT have involved a variety of CO monitoring devices but none has been widely adopted for routine use. Hence, we should keep in mind that a variety of factors (institutional, device related, cost, experience, severity of diseases, heart rhythm, type of interventions, degree of invasiveness, safety, personal convenience, adaptability, etc.) influence the selection of a CO monitoring device in our current clinical practice. Thus, it is critical that clinicians understand each approaches underlying technical principles and inherent limitations. Generally, GDT is easier to implement with the newer technologies because they require less training and, in most cases, are more easily interpreted by the majority of clinicians. When assessing the reliability and clinical use of a noninvasive CO device, 2 factors are important: the accuracy of individual measurements compared with the reference method and the ability to track dynamic changes in CO accurately after a therapeutic intervention.
As demonstrated in a meta-analysis by Peyton [31] , most of the available technologies (pulse contour Fig. 1 The classic relationship between perioperative volume status and perioperative complications. The relationship describes a ''U'' shape with an increased risk of complication for both perioperative hypovolemia and perioperative hypervolemia, emphasizing the importance of perioperative fluid optimization techniques, esophageal Doppler, partial carbon dioxide rebreathing, and bioimpedance) did not achieve a percentage error of agreement with thermodilution of B30 % suggested by Critchley and Critchley [32] . However, although important, the percentage error of agreement is only one marker of acceptability. In our opinion, the device capacity to track real time changes in CO may be more important than the ability of the monitor to deliver a highly accurate single measurement. This is especially true in hemodynamically unstable patients [33, 34] because it directly impacts the immediate clinical decision making and therapeutic interventions.
We will describe below the most common and relevant technologies used for GDT. Table 2 shows the list of all hemodynamic monitoring systems and describes their clinical potential.
Pulmonary Artery Catheter
The PAC obtains direct measurements of central venous, right-sided intracardiac, pulmonary arterial, and pulmonary artery wedge pressures. Moreover, it can estimate CO, systemic vascular resistance, and pulmonary vascular resistance. PAC is therefore considered to be the reference CO monitoring standard against which all new CO devices have been compared. Even though it is considered the current gold standard, its accuracy is between 12 and 15 % for triplicate injection of iced saline and even worse under other specific conditions (elderly, obesity, less than three injections) [35, 36] . Functionally, other patients conditions (mitral or tricuspid valve insufficiency, shunt) or misplacement of the PAC may influence reliable CO assessment [37] . Insertion of PAC is associated with an increased risk of various perioperative complications such as arrhythmia, air embolism, pneumothorax, and pulmonary artery rupture [38] . Also, some studies have suggested that the use of PAC for critically ill patients does not actually improve outcome [39] [40] [41] [42] [43] [44] . Even with the current risk-to-reward ratio, this device can still occasionally be useful for critically ill patients with low CO undergoing cardiac surgeries and even more rarely in very sick cardiac patients undergoing non-cardiac surgery. As the PAC's dominance is dwindling in the ICU, its prospects in the OR are also threatened by the growing application of transesophageal echocardiography (TEE). The ASA guidelines currently suggest that the decision to utilize a PAC depends on a hazy combination of risks derived from the patient, the surgery, and the practice setting. Essentially, this decision should be made on a case-by-case basis.
Pulse Contour Analysis
Pulse contour analysis systems are based on the relationship between SV, peripheral vascular resistance, arterial pressure, and arterial compliance [45] . These systems measure CO indirectly from an arterial waveform analysis. Seven systems using different analysis algorithms are available, which are divided into 2 groups: (1) pulse contour analysis system, which needs a dilution CO measurement for calibration (PiCCO: Pulsion Medical Systems, Munish, Germany; Volume view: Edwards Lifesciences, Irvine, CA, USA; and LiDCO plus: LiDCO, London, UK), and (2) pulse contour analysis system requiring no calibration (LiDCO rapid: LiDCO, London, UK; Vigileo-FloTrac: Edwards Lifesciences, Irvine, CA, USA; PRAM: Vyetech Health, Padua, Italy; and Pulsioflex: Pulsion Medical Systems, Munish, Germany). The accuracy of the pulse pressure analysis method in estimating CO has been extensively investigated against CO calculations by thermodilution method using the PAC. One example is a recent meta-analysis [46] for the Flotrac/ Vigileo that showed improved correlation between this device and the thermodilution method when the new generation software was used as opposed to the initially poor correlation with previous generations. Once again, we must take into consideration that pulse pressure analysis may be of limited accuracy during periods of hemodynamic instability (i.e., rapid changes in vascular resistance) and this may especially be a problem for uncalibrated pulse pressure analysis. In contrast, although calibrated pulse pressure analysis may prove more accurate, they may also require frequent recalibration to maintain continued accuracy.
These systems are also able to measure dynamic indices of fluid responsiveness, including pulse pressure variation (PPV) and stroke volume variation (SVV). In the past decades, it has been shown that static indices such as CVP, PCWP, left ventricular end diastolic area, and right ventricular end-diastolic volume are not accurate for the prediction of fluid responsiveness [13, [47] [48] [49] [50] [51] . In contrast, several studies have shown that dynamic indices, such as SVV and PPV, are able to predict fluid responsiveness accurately [52] [53] [54] [55] [56] . However, dynamic indices based on cardiopulmonary interactions have several limitations. First, these variables should only be assessed in patients who are properly anesthetized on mechanical ventilation [57] . Moreover, tidal volume has an impact on the predictive reliability of SVV and PPV and the tidal volume must be at least 6 ml/kg to allow PPV or SVV to predict fluid responsiveness [58] . As expected, patients must be in sinus rhythm, closed-chest, and experiencing normal intraabdominal pressure [59] . Despite a strong predictive value, PPV results may fall within the inconclusive ''gray zone'' (between 9 % and 13 %) in approximately 25 % of patients during general anesthesia [52] . Both cardiovascular (rhythm, cardiac function, ventricular afterload, and heart rate) and respiratory issues (tidal volume, positive endexpiratory pressure, lung compliance, and chest compliance) need to be acknowledged. All of these limitations have to be considered before using dynamic indices in the OR or ICU settings.
Non-invasive Monitoring

Ultrasound
Briefly, the velocity of any moving object can be estimated by analyzing the frequency difference between the incident and reflected ultrasound waves. The Doppler equation defines this relationship more precisely with (v) the velocity of the target, (h) the incident angle, (c) speed of sound in the medium, (Df) the frequency difference, and (f 0 ) the frequency of the originally emitted ultrasound beam.
Clinically, the esophageal Doppler (CardioQ; Deltex Medical, Chichester, UK) provides hemodynamic data including SV, SVV, CO, and corrected flow time (FTc) by utilizing this equation to measure blood flow velocity in the descending aorta. The probe is placed in the esophagus and then rotated to the direction facing the descending aorta. CO is then calculated by measuring the flow velocity of blood. The diameter of the aorta is calculated based on the patient's demographics. FTc is inversely correlated with the systemic vascular resistance and, thus a common reason for short FTc (\330 ms) is hypovolemia. One concern for the use of esophageal Doppler (EDM) in CO measurement is determining if the ratio of blood entering the descending aorta from the left ventricle is constant. Previous studies have shown that in patients with unstable hemodynamic state, a disproportionate percentage of the CO increase following volume loading was directed to the carotid arteries [60] . Therefore, when conducting GDT based on esophageal Doppler in critically ill patients, one has to keep in mind that an increase in blood velocity in the descending aorta may not necessarily correlate with an increase in total SV [61] . However, to date, esophageal Doppler is the device with the most positive GDT studies in the perioperative setting.
The USCOM system (USCOM Ltd, Sydney, Australia) is also a noninvasive monitoring device using Doppler technology to measure stroke SV and its derived parameters. The probe of the USCOM system is positioned at the supraclavicular or suprasternal notch to measure blood flow of the left and right ventricular outflow tracts. This system is completely non-invasive and requires no calibration. However, it is observer-dependent and does not provide continuous information. Unfortunately, there are currently not enough validation studies employing this monitor. Thom et al. [62] reported poor agreement between CO measurements done with the USCOM system and PAC. On the other hand, Chand et al. [63] revealed good correlation in the same type of patients. Further studies are needed to fully validate this approach in various clinical settings.
Plethysmography
Pleth variability index (PVI) (Masimo Corp., Irvine, CA, USA) has been the most widely studied noninvasive monitoring system when looking specifically at GDT. PVI measures the minimal and maximal plethysmographic waveform amplitudes (DPOP) during respiratory cycle and calculates the percentage difference. PVI has been shown to be a good predictor of fluid responsiveness in the OR and ICU [64, 65] . A recent meta-analysis [66] concluded that PVI had acceptable reliability in predicting fluid responsiveness in ventilated patients. However, changes in vasomotor tone, vasopressors administration, and other conditions such as hypothermia have a direct impact on the plethysmographic waveform and should be well known as its potential limitations [67, 68] . Consequently, PVI should continue to be analyzed under stable and unstable conditions in order to more accurately determine the specific limitations.
Non-calibrated Pulse Contour Analysis
The Nexfin (Edwards Lifesciences, Irvine, CA) is a particularly novel non-invasive CO monitor among the various devices available today. This system estimates CO in two steps. First, this system includes cuffs to be wrapped around the patient's fingers that enable a continuous measurement of the arterial pressure curve based on the volume-clamp methodology [69] . This approach utilizes a photoplethysmographic device that measures the diameter of the arteries in the finger. A fast servo-controlled system inflates the cuff wrapped around the finger to maintain the arteries' diameter in the finger constant, which then allows the cuff pressures to estimate the arterial blood pressure. Second, the Nexfin device estimates CO based on a pulse contour analysis methodology described by Bogert et al. [70] . This device has been somewhat largely validated for CO monitoring and shows promise for future GDT trials [69, [71] [72] [73] .
Thoracic Electrical Bioimpedance
This technique was founded on the concept that electrical conducting properties of the thoracic space vary with the amount of blood contained therein. Measurements of CO are made by measuring changes in determining flow (I) and thoracic impedance (Z) based on its relationship to electrical potential difference (E) that are defined by Ohm's law:
Recently, concerns have surfaced over the levels of accuracy of CO achieved with this technology and it has been shown a poor agreement between thoracic electrical bioimpedance and the reference method. [74] [75] [76] . Variance in electric skin conductivity between the body and the electrodes including temperature and humidity [77, 78] , patient movement and lack of clinician attention to exact placement of sticker-electrodes and electric noise may contribute to inaccurate and variables measurements reading [77, 79, 80] .
Bioreactance
Because of the limitations of bioimpedance devices, bioreactance technology, which is newer method of processing the impedance signal, has been developed and is based on the discovery that changes in aortic blood volume induce small changes in the frequency of electrical signals propagating across the thorax. The NICOM system (Cheetah Medical, Portland, OR) uses an algorithm which measures phase shifts in high-frequency waves transmitted across the thorax, with a nearly 100-fold improvement in the signal-to-noise ratio and thus in an improved performance of this technology. This device consists of four pads placed across the thorax which are connected to a monitor [81] . CO assessment by the NICOM system can be achieved in nonventilated and ventilated patients alike, and can be computed in patients with cardiac arrhythmias. The NICOM system has been validated with clinically acceptable reliability when compared with PAC in critically ill patients [82, 83] . A recently published study using the bioreactance technology as a GDT monitor has been shown to perform similarly to the Esophageal Doppler method [81] .
Partial CO 2 Re-inhalation CO can be calculated by the CO 2 partial rebreathing technique using the modified Fick equation [84] . The NICO device (Novametrix Medical Systems, Wallingford, USA) measures CO on this principle. This system has some limitations including, but not limited to, false CO 2 changes obtained both in ventilation and dead space. There are currently few validation studies of this system. Kotake et al. [85] demonstrated a poor agreement of this system in CO measurement against PAC in cardiac surgical patients. Overall, this system is presently not interchangeable for PAC, but constitutes a feasible alternative in critically ill patients in the future if reasonable evidence emerges.
Additional Hemodynamic Variables
ScvO 2
Monitoring of mixed venous oxygen saturation (SvO 2 ) has been used as a simple method for evaluating changes in the systemic oxygen supply to demand ratio in various clinical settings [39, 41] . Unfortunately, a PAC is currently required to obtain SvO 2 . Fortunately, ScvO 2 may represent an attractive alternative because it can more easily be measured using a central venous catheter. Reinhart et al. have shown that ScvO 2 has a good correlation with SvO 2 [86] . However, there is still debate regarding the equivalence between these two values [87] [88] [89] [90] especially when they are low [91] . The surviving Sepsis Campaign recognized the clinical importance of ScvO 2 and recommended to keep ScvO 2 more than 70 % during the resuscitation of septic shock patients. A multi-center study to assess the incidence of low ScvO 2 in high-risk surgical patients revealed that the low ScvO 2 correlated with an increased risk of postoperative complications in high-risk surgical patients [92] . They also determined that the best cut-off value for ScvO 2 in predicting postoperative complications was 73 % [92] . However, more recently, the multicenter, randomized protocolized care for early septic shock (ProCESS) trial was conducted at 31 hospitals in the United States and revealed that protocol-based GDT including the use of ScvO 2 did not improve the outcomes in septic patients [93 •• ] . As CVP access is common in high risk patients, there is still much room for growth in using ScvO 2 for GDT in this patient population. Hopefully future research protocols will address such a knowledge gap.
Veno-arterial Carbon Dioxide Gradient (P(v-a)CO 2 )
The central venous to arterial carbon dioxide difference P(v-a)CO 2 has been proposed by some authors for assessment of tissue perfusion [94, 95] . Values of P(v-a)CO 2 larger than 6 mmHg were found to be associated with poor outcome and organ dysfunctions [94, 96] . Additional research on the defined clinical practicality of this variable is pending.
Cerebral Oximetry
Cerebral oximetry estimates the oxygenation of regional tissue by transcutaneous measurement of the frontal cerebral cortex, which is an area of the brain that is particularly susceptible to hypoxia [97] . In fact, the brain receives around 20 % of the CO and, concordantly, consumes approximately 20 % of the total body oxygen. Therefore, cerebral oximetry has gained increasing popularity as a monitor capable of detecting cerebral ischemia.
Beyond providing continuous insight into regional oxygenation of the brain, cerebral oximetry may provide additional utility for patient care. For instance, it may allow clinicians to use the brain as an index organ that represents the adequacy of tissue perfusion and oxygenation of other vital organs. Also, there is increasing interest in the utilization of similar oximetry sensors to monitor adequacy of tissue perfusion when placed on non-cerebral anatomic sites in both adult and pediatric patients [98, 99] .
Significant falls in rSO 2 have been shown to predict poor outcomes (cerebral and non-cerebral) in cardiac and non-cardiac surgical patients [100] [101] [102] . The most important approach is to maintain rSO 2 within 20 % of baseline in these patient groups in order to reduce postoperative complications [101, 103] . This monitoring device is an early warning system for picking up imbalances between cerebral oxygen supply and demand, especially deficient cerebral oxygen delivery, and acts as an indicator of cerebral ischemia. The maintenance of an adequate cerebral oxygenation helps to ensure intraoperative optimization of oxygen delivery and may improve outcomes [104] . It seems to be a promising technology but has not been formally evaluated in a formalized GDT protocol.
How to Apply GDT in the Operating Room
In this chapter, we will discuss how some of the devices described in the previous section have been used in the OR alongside standardized protocols and how this implementation has impacted patient outcome. Table 3 shows the most famous GDT protocols in the OR in patients undergoing major surgery.
It is well known that patients with stronger preoperative risk factors are less likely to survive the procedure and more likely to develop post-surgical complications. As such, GDT in high risk surgical patients is likely to have the greatest benefit if carried out early with a predefined protocol. In a recent meta-analysis investigating the effect of GDT on different risk groups [105 •• ] , the mortality benefit of GDT was limited to the extremely high-risk group patients [odds ratio (OR) = 0.27, 95 % confidence interval (CI) 0.15-0.51, p \ 0.00001). Complication rates were reduced in all risk subgroups (OR = 0.45, 95 % CI 0.34-0.60, p \ 0.00001). Pearse et al. [26 • • ] conducted a randomized clinical trial in 734 high-risk patients undergoing major gastrointestinal surgery, and revealed that GDT using CO-guided hemodynamic management did not provide significant decreases in 30-day major complications and mortality (relative risk = 0.84, 95 % CI 0.71-1.01). However, in a meta-analysis of 38 trials including this data, they also indicated that the hemodynamic intervention was related to a reduction in postoperative complications (intervention 31.5 %, control 41.6 %; relative risk = 0.77, 95 % CI 0.71-0.83). It should be mentioned that one must remember to consider publication bias in such a study as negative results are much more difficult to publish and less pursued by investigators when compared to positive results.
The first step for proper GDT implementation in the OR is to identify the patient's surgical risk and to determine appropriate vascular access. Once established, one can choose the best available monitoring approach and the suitable hemodynamic optimization protocol. Figure 2 lists appropriate suggestions for the choice of the hemodynamic monitoring system based on a patient's risk factors and vascular access. The main message to keep in mind is that choosing the most appropriate hemodynamic monitor is ''context dependent'' (''no high heels on the farm, no clogs to the opera'') [106] . During high risk surgery, invasive or minimally invasive monitoring devices (more robust signals, better accuracy) are more suitable in hemodynamically unstable patients or when postoperative complications are likely to occur (best therapeutic decision making). In other lower risk cases, the risks associated with an invasive monitor outweigh its expected benefits. For these situations, clinicians may choose accept the lower accuracy provided by noninvasive CO monitoring devices because there is no justification in using invasive arterial lines in patients who are at lower risks just because the device is more accurate.
Protocol for Low Risk Surgery
Low risk surgery is defined as meeting all of the following criteria: (1) patient is classified as American Society Anesthesiologist (ASA) physical status 1 or 2, (2) the surgery has expected blood loss less than 500 ml, and (3) the surgical case is either gynecologic, breast, ophthalmologic, stomatologic, endocrinology (except pheochromocytoma and carcinoid tumor), minor urologic, plastic, or minor orthopedic. In a recent simulation study of GDT, it was shown that GDT is cost-effective and associated with cost savings [107] . Therefore, in low risk patients, it is recommended to use peripheral intravenous access and, in addition to the standard monitors, employ a non-invasive hemodynamic monitor for GDT such as PVI. Figure 3 shows an example protocol for GDT using PVI. The goal for GDT in this example is to use a baseline crystalloid administration of 3 to 5 ml/kg/h and then to titrate volume expansion using PVI. Forget et al. [108] conducted a randomized controlled trial (RCT) to investigate the impact of GDT using PVI in patients scheduled for major abdominal surgery. The PVI group patients were administered colloids of 250 mL if the PVI was over 13 %. As the result, intraoperative infusion volume was significantly lower in the PVI group. Lactate levels were significantly lower in the PVI group during surgery and 48 h after surgery (p \ 0.05).
Protocol for Moderate Risk Surgery
Moderate risk surgery is defined as follows: (1) patient is classified as ASA physical status 2 or 3,(2) the expected blood loss is less than 1500 ml, and (3) the surgery type is either abdominal, head and neck, major orthopedic surgery, peripheral angiography, kidney transplantation, or urologic. For these moderate risk surgical patients, one can use one or two peripheral intravenous lines and/or an arterial line.
• In patients without an arterial line, the ''NICE protocol'' released in March 2011 by the NHS in the UK [109] can be applied (Fig. 4) . The goal is to titrate fluid loading in order to maximize SV. Also, the GDT protocol suggested by Gan et al. [16] can be used (Fig. 5) . They reported lower incidence of postoperative nausea and vomiting, earlier return to bowel function, and decrease in length of postoperative hospital stay using the esophageal doppler to maximize SV.
• In patients with arterial lines, CO monitoring based on arterial pressure waveform can be applied for GDT protocol. Figure 6 demonstrates an example of a GDT algorithm using SVV and PPV in the OR that can be applied this situation. When employing SVV or PPV for GDT, the patient should be intubated with general anesthesia, have a sinus rhythm, and have a tidal volume [8 mL/kg. Ramsingh et al. [110] conducted a GDT protocol (Fig. 7) to maintain SVV\12 % using the Vigileo-FloTrac system in low to moderate risk patients undergoing high risk abdominal surgery. They reported that the GDT group patients had faster return of gastrointestinal function (p = 0.004) and higher ''quality of recovery'' scores.
Protocol for High Risk Surgery
Upgrading surgical patients from moderate risk to high risk is dependent on surgical criteria, patient-related factors and/ or formal dynamic testing of functional capacity. High risk surgical patients are those with an individual mortality risk greater than 5 % or undergoing a surgery carrying a 5 % mortality. These patients commonly have a limited physiological cardiopulmonary reserve and an inability to meet the increased oxygen demand imposed by the perioperative surgical stress during major surgery which is associated with a significant mortality risk. In addition to these patient specific risk factors, perioperative risk factors include multiple interventions that can negatively influence the balance between oxygen demand and consumption. Nociceptive surgical stimulations, volume variations due to acute blood losses or transfusions and administration of anesthetic agent can significantly influence this VO 2 -DO 2 relationship. Some studies evaluated the VO 2 -DO 2 relationship in major surgery [111] [112] [113] and showed a decreased capacity for tissue O 2 extraction which may have lead to tissue hypoxia [114] . These observations demonstrate the importance of adequately evaluating the DO 2 -VO 2 relationship in conjunction with the patient's metabolic demand, which is once again strongly affected by surgical conditions. Initially, significant perioperative cardiopulmonary optimization information came from observational data [115] . He recognized that, during the perioperative period, patient developed an ''oxygen debt'' (imbalance between global oxygen delivery and oxygen consumption). If their cardiopulmonary reserve was limited, they were less likely to meet the increased oxygen demand incurred during major surgery [116] . He used predefined hemodynamic measures (oxygen delivery index) to guide therapy and observed that patients who survived from major surgery had higher DO 2 values than non survivors. Using these data, an early GDT aimed at supra optimizing postoperative DO 2 resulted in lowered complications, LOS, mechanical ventilation, and overall cost. The patients who experienced postoperative complications tended to be those that could also not increase their CO to meet the increased demand of surgery. However, this approach is not beneficial to every high risk surgical patient because their level of oxygen demand, degree of cardiac function alteration, and capacities of oxygen extraction may significantly vary. Thus, the major concern of the anesthetist in the perioperative period is to optimize the patient's individual volemic status by aiming to achieve well-defined goals (based on flow related parameters such as stroke volume) in order to maximize end organ oxygen delivery. SvO 2 can give information about tissue oxygen consumption and can be collected in conjunction with CO and multiple other cardiopulmonary variables during PAC catheterization. Lobo et al. [117] conducted a RCT to investigate the impact of GDT (using PAC) on postoperative outcomes in high-risk surgical patients undergoing major abdominal surgery. The GDT group was managed with the goal of supranormal values (oxygen delivery index [600 mL/min m 2 ). They reported a decrease in cardiovascular complications and 60-day mortality rates in the GDT group. Unfortunately, SvO 2 and other cardiopulmonary variables require a PAC insertion, which comes with inherent risks only rarely clinically justifiable [118] . As mentioned above, collecting ScvO 2 for use as a GDT endpoint is more easily accessible through a central venous catheter. Donati et al. [119] revealed improved outcomes in GDT group patients using dobutamine and fluids titrated to optimize oxygen extraction less than 27 % (ScvO 2 [73 %). Additionally, a decreased ScvO 2 in the perioperative period is independently correlated with increased postoperative complications [120] . Regardless, there is still room for further ScvO 2 clinical research, especially as it pertains to high surgical risk GDT. Figure 8 shows an example protocol using ScvO 2 adapted from the report by Vallet et al. [121] .
Once again, as with any emergent technology, GDT is meant to be used as one piece of a much larger puzzle and should be interpreted within the wider clinical context in an individualized approach.
Future Perspectives: Closed-Loop Fluid Administration System
What is the next step for GDT? As this evidence-based approach to fluid management becomes more consistently accepted among leading institutions around the world, we believe the next step is closing the automation loop between data collection and fluid management interventions. It is best to think of this closed loop as powerful but easily broken if the physician anesthesiologist encounters a clinical situation where standardization may not be the best approach. At UC Irvine Medical Center (Orange, CA, USA), we have recently described a novel-closed loop fluid administration system based on SV monitoring and optimization (Learning Intravenous Resuscitator Ó ) [122, 123] . The aim of this system is to ease implementation of protocols in clinical settings and to apply goal-directed fluid therapy automatically. After conducting simulation [122, 123] , engineering [124] , and animal studies [125] , it is now starting to be used in the OR with semi-invasive [126] and, more recently, non-invasive devices.
This system is designed to titrate the fluid administration rate until stroke volume reaches the plateau of the Frankstarling relationship. Once accomplished, the next step is to then maintain the patient's volume status on that plateau throughout the surgical intervention. To achieve this goal, the closed-loop system monitors SV, tracks volume expansion-induced changes in SV and uses PPV or SVV to refine fluid responsiveness predictions [30, 52] . The benefits seem already obvious: targeting a parameter with greater accuracy, decreasing the hemodynamic variability, reducing inattention and human error, and allowing the clinician to concentrate on other tasks. This system is certainly not designed to replace the physician anesthesiologist, just as aviation closed-loop systems (e.g. autopilot) are not designed to replace the pilot. Similarly, this new technology should increase safety by reducing variability and improving patient outcome. It is important to note that future clinical studies are indicated to confirm the real benefit of this system in the anesthesia setting even if the primary results of current clinical trials have shown that the overall strategy is feasible and encouraging.
Conclusions
The importance of goal-directed perioperativehemodynamic optimization has increased in the past decade and has evolved alongside hemodynamic monitoring technology. As a result, endpoints used for this optimization have also advanced, with a shift from more static to more dynamic variables. Using such goal-directed therapies, there is growing evidence in moderate to high risk surgical Fig. 2 PVI pleth variability index, SVV stroke volume variation, PPV pulse pressure variation, ICU intensive care unit, ScvO 2 central venous oxygen saturation, PAC pulmonary artery catheter, TEE transesophageal echocardiography. A suggestion for the choice of the hemodynamic monitoring systembased on patient's risk and vascular access. The first step for goal-directed therapy in the operating room is to identify the risk of surgical patients and then to decide the vascular access Fig. 6 SVV stroke volume variation, PPV pulse pressure variation. The example protocol for goal-directed therapy using the SVV or PPV. The goal for goal-directed therapy is to titrate volume expansion based on SVV or PPV. In this protocol, the goal for SVV or PPV is less than 13 % Fig. 3 PVI pleth variability index. The example protocol for goaldirected therapy using PVI. The goal for goal-directed therapy is to use a baseline crystalloid administration and to titrate volume expansion based on PVI. In this protocol, the goal for PVI is to be less than 15 % patients that appropriate treatment algorithms can improve outcomes especially if carried out early and in an individualized manner. As such, the increasing age and comorbidities of the surgical population clearly justify the use of advanced monitoring devices during the perioperative period. Nevertheless, some considerations need to be taken into account in the preoperative period when deciding to implement such devices in order to choose the right monitoring technology in the perioperative period (types of patient and surgery presence of an arterial line, exact knowledge of the device as well as its inherent limitations).
Despite all the evidence demonstrating the benefit of GDT, there is still no clear consensus about the most effective goals and the most appropriate monitoring device for guiding therapy. In fact, many endpoints and CO monitoring systems have been tested, both invasive and noninvasive, all with their own advantages and disadvantages. This has led to confusion in clinical practice about which device to use and within what specific algorithm. It is important to note that there are still only limited data showing that any of these specific monitoring devices will improve patient's outcome. Concordantly, the physician is held responsible for the correct understanding and interpretation of the available technologic and clinical data. One must then individualize and integrate such data into a full clinical picture of the patient in order to determine the best intervention.
Further creation, development and implementation of institutional perioperative GDT protocols and guidelines specific to the patients' status and type of surgery are necessary to minimize variability between clinicians and thus improve hemodynamic stability, optimize tissue perfusion, and decrease postoperative complications. Hopefully, these needs have begun to be considered by clinicians and departments in the wake of the recently developed ERAS program, PSH model, and the automatic closed-loop fluid administration system. 
